A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being teste
| Condition(s) | Obesity, Knee Osteoarthritis (OA) |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Summary | The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance. |
| Who can participate | Key inclusion Criteria: * Male or female (sex at birth). * Age 18 years or above at the time of signing the informed consent. * Clinical diagnosis of knee osteoarthritis (American College of Rheumatology criteria) with radiographic changes (Kellgren Lawrence (KL) grades 2 to 3 as per central reading) in target knee. Target knee joint is defined as most symptomatic knee at screening. If pain in knees is equal, the target knee joint will be the dominant leg. * Symptomatic knee OA with first appearance of pain in the target knee more than (\>) 90 days prior to screening and pain in the target knee for \> 15 days over the prior 30 days. * Willingness to complete a 72-hour washout period of analgesics before all visits involving WOMAC Osteoarthritis Index NRS 3.1 (24-hour) (WOMAC) questionnaire |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Novo Nordisk A/S |
| Locations | Phoenix, Arizona, United States; Walnut Creek, California, United States; Hamden, Connecticut, United States; Waterbury, Connecticut, United States; Hollywood, Florida, United States; Jacksonville, Florida, United States (+76 more sites) |
| Start date | 2026-04-13 |
| NCT ID | NCT07481630 |
| Official listing | https://clinicaltrials.gov/study/NCT07481630 |